Literature DB >> 30209605

Impaired activity of daily living is a risk factor for high medical cost in patients of non-variceal upper gastrointestinal bleeding.

Yusaku Takatori1,2, Motohiko Kato3, Yukie Sunata1, Yuichiro Hirai1, Yoko Kubosawa1, Keichiro Abe1, Yoshiaki Takada1, Tetsu Hirata1, Shigeo Banno1, Michiko Wada1, Satoshi Kinoshita1, Hideki Mori1, Kaoru Takabayashi1, Miho Kikuchi1, Masahiro Kikuchi1, Masayuki Suzuki1, Toshio Uraoka1.   

Abstract

BACKGROUND: Non-variceal upper gastrointestinal bleeding (NVUGIB) is still a common and life-threatening disease, thus it would have a big impact on medical care cost. However, little is known about risk factors for increased medical care cost in NVUGIB patients. AIM: The purpose of the study was to clarify predictor of requiring high medical care cost in NVUGIB patients. Patients who underwent endoscopic hemostasis due to NVUGIB between April 2012 and March 2015 were included in this retrospective study. We analyzed the association between patients' background including activity of daily livings (ADL) and high medical care cost using logistic regression model. Medical care cost was calculated in reference to the "Diagnosis Procedure Combination" which is diagnosis-dominant case-mix system in Japan. The cutoff value of high medical care cost was defined as its first quartile. ADL was assessed according to Katz-6 score. We defined impaired ADL patient who revealed Katz-6 score more than 1.
RESULTS: A total of 128 consecutive patients were included in this study. Median medical care cost was 5323 USD (IQR 3661-8172 USD). There were 13 patients (10%) in impaired ADL group. In univariate analysis, age and impaired ADL before admission revealed significant association with high cost. Of these, impaired ADL was an only independent risk factor [odds ratio 15.3 (95% CI 2.49-183)] in multivariate analysis.
CONCLUSION: Impairment in ADL before admission was an independent predictor for high medical care cost with NVUGIB patients.

Entities:  

Keywords:  ADL; Activity of daily living; Impaired; Medical care cost; NVUGIB; Non-variceal upper gastrointestinal bleeding

Year:  2018        PMID: 30209605     DOI: 10.1007/s00464-018-6433-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  The clinical and cost implications of failed endoscopic hemostasis in gastroduodenal ulcer bleeding.

Authors:  Ann Roy; Micheline Kim; Robert Hawes; Shyam Varadarajulu
Journal:  United European Gastroenterol J       Date:  2016-08-02       Impact factor: 4.623

2.  Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002.

Authors:  J Y Kang; A Elders; A Majeed; J D Maxwell; K D Bardhan
Journal:  Aliment Pharmacol Ther       Date:  2006-07-01       Impact factor: 8.171

3.  Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects.

Authors:  J Higham; J-Y Kang; A Majeed
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

4.  Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.

Authors:  J T Edelson; A N Tosteson; P Sax
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

5.  Progress in development of the index of ADL.

Authors:  S Katz; T D Downs; H R Cash; R C Grotz
Journal:  Gerontologist       Date:  1970

6.  [Value and economic analysis of emergency endoscopy in the diagnosis and treatment of massive upper gastrointestinal hemorrhage].

Authors:  Ai-hua Gan; Au-gao Xu; Hong Ling; Hui-xin Chen; Yu-ming Zhang; Zhi-yong Tong; Xu-hui Zhong; Yong-cheng Xu
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2003-12

7.  Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.

Authors:  K K C Lee; J H S You; J T S Ho; B Y Suen; M Y Yung; W H Lau; V W Y Lee; J Y Sung; F K L Chan
Journal:  Aliment Pharmacol Ther       Date:  2003-07-15       Impact factor: 8.171

8.  Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.

Authors:  Sameer D Saini; Philip Schoenfeld; A Mark Fendrick; James Scheiman
Journal:  Arch Intern Med       Date:  2008-08-11

9.  Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.

Authors:  Catherine Reed; Mark Belger; Bruno Vellas; Jeffrey Scott Andrews; Josep M Argimon; Giuseppe Bruno; Richard Dodel; Roy W Jones; Anders Wimo; Josep Maria Haro
Journal:  Int Psychogeriatr       Date:  2015-08-26       Impact factor: 3.878

10.  Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.

Authors:  Pierluigi Russo; Chiara Brutti
Journal:  Clin Ther       Date:  2007-04       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.